Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Melanoma

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 80 articles:
HTML format
Text format



Single Articles


    June 2018
  1. PIRLAMARLA AK, Tang J, Amin B, Kabarriti R, et al
    Vulvar Melanoma with Isolated Metastasis to the Extraocular Muscles: Case Report and Brief Literature Review.
    Anticancer Res. 2018;38:3763-3766.
    PubMed     Text format     Abstract available


  2. MANTAS D, Damaskos C, Garmpis N, Dimitroulis D, et al
    Abdominal Emergencies in Patients with Stage IV Melanoma: The Role of Surgery: A Single-centre Experience.
    Anticancer Res. 2018;38:3713-3718.
    PubMed     Text format     Abstract available


  3. SAKAMOTO A, Kato K, Hasegawa T, Ikeda S, et al
    An Agonistic Antibody to EPHA2 Exhibits Antitumor Effects on Human Melanoma Cells.
    Anticancer Res. 2018;38:3273-3282.
    PubMed     Text format     Abstract available


    May 2018
  4. MOSCHOS MM, Moustafa GA, Lavaris A, Damaskos C, et al
    Depression in Choroidal Melanoma Patients Treated with Proton Beam Radiotherapy.
    Anticancer Res. 2018;38:3055-3061.
    PubMed     Text format     Abstract available


  5. AL-QURAYSHI Z, Crowther JE, Hamner JB, Ducoin C, et al
    Disparities of Immunotherapy Utilization in Patients with Stage III Cutaneous Melanoma: A National Perspective.
    Anticancer Res. 2018;38:2897-2901.
    PubMed     Text format     Abstract available


    March 2018
  6. WALTER L, Heinzerling L
    BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma.
    Anticancer Res. 2018;38:1335-1341.
    PubMed     Text format     Abstract available


    February 2018
  7. BURGARD B, Schope J, Holzschuh I, Schiekofer C, et al
    Solarium Use and Risk for Malignant Melanoma: Meta-analysis and Evidence-based Medicine Systematic Review.
    Anticancer Res. 2018;38:1187-1199.
    PubMed     Text format     Abstract available


  8. GRECO M, Arcidiacono B, Chiefari E, Vitagliano T, et al
    HMGA1 and MMP-11 Are Overexpressed in Human Non-melanoma Skin Cancer.
    Anticancer Res. 2018;38:771-778.
    PubMed     Text format     Abstract available


  9. REICHRATH J, Lindqvist PG, DE Gruijl FR, Pilz S, et al
    A Critical Appraisal of the Recent Reports on Sunbeds from the European Commission's Scientific Committee on Health, Environmental and Emerging Risks and from the World Health Organization.
    Anticancer Res. 2018;38:1111-1120.
    PubMed     Text format     Abstract available


    January 2018

  10. Cutaneous Melanoma. 1st Edition. A Pocket Guide for Diagnosis and Management.
    Anticancer Res. 2018;38:587.
    PubMed     Text format    


    December 2017
  11. PONTI G, Manfredini M, Greco S, Pellacani G, et al
    BRAF, NRAS and C-KIT Advanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival.
    Anticancer Res. 2017;37:7043-7048.
    PubMed     Text format     Abstract available


  12. RAPI V, Dogan A, Schultheis B, Hartmann F, et al
    Melanoma of the Vagina: Case Report and Systematic Review of the Literature.
    Anticancer Res. 2017;37:6911-6920.
    PubMed     Text format     Abstract available


  13. DELGADO AF, Delgado AF
    Complete Lymph Node Dissection in Melanoma: A Systematic Review and Meta-Analysis.
    Anticancer Res. 2017;37:6825-6829.
    PubMed     Text format     Abstract available


  14. WOZNIAK M, Peczek L, Czernek L, Duchler M, et al
    Analysis of the miRNA Profiles of Melanoma Exosomes Derived Under Normoxic and Hypoxic Culture Conditions.
    Anticancer Res. 2017;37:6779-6789.
    PubMed     Text format     Abstract available


  15. YANAROJANA M, Nararatwanchai T, Thairat S, Tancharoen S, et al
    Antiproliferative Activity and Induction of Apoptosis in Human Melanoma Cells by Houttuynia cordata Thunb Extract.
    Anticancer Res. 2017;37:6619-6628.
    PubMed     Text format     Abstract available


  16. BERUS T, Halon A, Markiewicz A, Orlowska-Heitzman J, et al
    Clinical, Histopathological and Cytogenetic Prognosticators in Uveal Melanoma - A Comprehensive Review.
    Anticancer Res. 2017;37:6541-6549.
    PubMed     Text format     Abstract available


    November 2017
  17. MA YS, Hsiao YT, Lin JJ, Liao CL, et al
    Phenethyl Isothiocyanate (PEITC) and Benzyl Isothiocyanate (BITC) Inhibit Human Melanoma A375.S2 Cell Migration and Invasion by Affecting MAPK Signaling Pathway In Vitro.
    Anticancer Res. 2017;37:6223-6234.
    PubMed     Text format     Abstract available


  18. NAJEM A, Krayem M, Perdrix A, Kerger J, et al
    New Drug Combination Strategies in Melanoma: Current Status and Future Directions.
    Anticancer Res. 2017;37:5941-5953.
    PubMed     Text format     Abstract available


    October 2017
  19. PSINAKIS F, Katseli A, Koutsandrea C, Frangia K, et al
    Uveal Melanoma: GNAQ and GNA11 Mutations in a Greek Population.
    Anticancer Res. 2017;37:5719-5726.
    PubMed     Text format     Abstract available


  20. HU WP, Kuo KK, Senadi GC, Chang LS, et al
    Photodynamic Therapy Using Indolines-Fused-Triazoles Induces Mitochondrial Apoptosis in Human Non-Melanoma BCC Cells.
    Anticancer Res. 2017;37:5499-5505.
    PubMed     Text format     Abstract available


  21. GARMPIS N, Damaskos C, Garmpi A, Dimitroulis D, et al
    Targeting Histone Deacetylases in Malignant Melanoma: A Future Therapeutic Agent or Just Great Expectations?
    Anticancer Res. 2017;37:5355-5362.
    PubMed     Text format     Abstract available


    September 2017
  22. USLU U, Schliep S, Schliep K, Erdmann M, et al
    Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells.
    Anticancer Res. 2017;37:5033-5037.
    PubMed     Text format     Abstract available


  23. SUCKOW MA, Wolter WR, Duffield GE
    The Impact of Environmental Light Intensity on Experimental Tumor Growth.
    Anticancer Res. 2017;37:4967-4971.
    PubMed     Text format     Abstract available


    August 2017
  24. KIM YJ, Song SY, Kim W, Jeong SY, et al
    Feasibility of Postoperative Radiotherapy Using Conventional Fractionation for Lymph Node Metastasis from Cutaneous Melanoma.
    Anticancer Res. 2017;37:4239-4246.
    PubMed     Text format     Abstract available


    July 2017
  25. USLU U, Schuler G, Breuninger H
    Factors Influencing Disease Progression in Patients with Head and Neck Melanoma.
    Anticancer Res. 2017;37:3811-3816.
    PubMed     Text format     Abstract available


  26. FURUDATE S, Fujimura T, Kambayashi Y, Kakizaki A, et al
    Immunomodulatory Effect of Imiquimod Through CCL22 Produced by Tumor-associated Macrophages in B16F10 Melanomas.
    Anticancer Res. 2017;37:3461-3471.
    PubMed     Text format     Abstract available


  27. NATH K, Nelson DS, Roman J, Putt ME, et al
    Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide.
    Anticancer Res. 2017;37:3413-3421.
    PubMed     Text format     Abstract available


  28. TANAKA T, Fujita M, Hasegawa H, Arimoto A, et al
    Frequency of Myeloid-derived Suppressor Cells in the Peripheral Blood Reflects the Status of Tumor Recurrence.
    Anticancer Res. 2017;37:3863-3869.
    PubMed     Text format     Abstract available


    June 2017
  29. USLU U, Erdmann M, Schliep S, Dorrie J, et al
    Sarcoidosis Under Dendritic Cell Vaccination Immunotherapy in Long-term Responding Patients with Metastatic Melanoma.
    Anticancer Res. 2017;37:3243-3248.
    PubMed     Text format     Abstract available


  30. JANIK ME, Szlezak D, Surman M, Golas A, et al
    Diversified beta-2-adrenergic Receptor Expression and Action in Melanoma Cells.
    Anticancer Res. 2017;37:3025-3033.
    PubMed     Text format     Abstract available


  31. LAUBE F, Glanz D
    Modulation of Melanotransferrin and Transferrin Receptor 1 (TFRC)- and CD44-based Signaling for TFRC Up-regulation in Human Melanoma Cells.
    Anticancer Res. 2017;37:3001-3007.
    PubMed     Text format     Abstract available


    April 2017
  32. YAMAUCHI K, Mitsunaga T, Afroze SH, Uddin MN, et al
    Structure-Activity Relationships of Methylquercetin on Anti-migration and Anti-proliferation Activity in B16 Melanoma Cells.
    Anticancer Res. 2017;37:1575-1579.
    PubMed     Text format     Abstract available


    March 2017

  33. Melanoma Development. Molecular Biology, Genetics and Clinical Application.
    Anticancer Res. 2017;37:1544.
    PubMed     Text format    


  34. YOSHIKAWA S, Kiyohara Y, Otsuka M, Kondou R, et al
    Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPE.
    Anticancer Res. 2017;37:1321-1328.
    PubMed     Text format     Abstract available


  35. LAWSON BO, Khong HT
    Narcoleptic-like Episodes in a Patient Receiving Pegylated Interferon-alpha 2b: A Case Report and Review of Literature.
    Anticancer Res. 2017;37:1365-1368.
    PubMed     Text format     Abstract available


  36. SPILIOPOULOS K, Peschos D, Batistatou A, Ntountas I, et al
    Immunohistochemical Study of Vasculogenic Mimicry and Angiogenesis in Melanocytic Tumors of the Eye and the Periocular Area.
    Anticancer Res. 2017;37:1113-1120.
    PubMed     Text format     Abstract available


    February 2017
  37. RYU SH, Heo SH, Park EY, Choi KC, et al
    Selumetinib Inhibits Melanoma Metastasis to Mouse Liver via Suppression of EMT-targeted Genes.
    Anticancer Res. 2017;37:607-614.
    PubMed     Text format     Abstract available


    January 2017
  38. SEHMISCH L, Schild SE, Rades D
    Development of a Survival Score for Patients with Cerebral Metastases from Melanoma.
    Anticancer Res. 2017;37:249-252.
    PubMed     Text format     Abstract available


  39. FORTIS SP, Anastasopoulou EA, Voutsas IF, Baxevanis CN, et al
    Potential Prognostic Molecular Signatures in a Preclinical Model of Melanoma.
    Anticancer Res. 2017;37:143-148.
    PubMed     Text format     Abstract available


  40. NGUYEN AH, Detty SQ, Agrawal DK
    Clinical Implications of High-mobility Group Box-1 (HMGB1) and the Receptor for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A Systematic Review.
    Anticancer Res. 2017;37:1-7.
    PubMed     Text format     Abstract available


    December 2016
  41. RADES D, Sehmisch L, Janssen S, Schild SE, et al
    Prognostic Factors After Whole-brain Radiotherapy Alone for Brain Metastases from Malignant Melanoma.
    Anticancer Res. 2016;36:6637-6640.
    PubMed     Text format     Abstract available


  42. NAFFOUJE SA, Naffouje R, Chen J, Salti GI, et al
    Validation and Enhancement of the Clinicopathological Melanoma Nomogram via Incorporation of a Molecular Marker in the Primary Tumor.
    Anticancer Res. 2016;36:6603-6610.
    PubMed     Text format     Abstract available


  43. SOLARI N, Gipponi M, Franco DS, Re F, et al
    Videoscopic Inguinal-iliac-obturator Lymph-node Dissection: New Videoscopic Technique for Regional Lymphadenectomy in Patients with Melanoma.
    Anticancer Res. 2016;36:6579-6583.
    PubMed     Text format     Abstract available


  44. YAN S, Holderness BM, Li Z, Seidel GD, et al
    Epithelial-Mesenchymal Expression Phenotype of Primary Melanoma and Matched Metastases and Relationship with Overall Survival.
    Anticancer Res. 2016;36:6449-6456.
    PubMed     Text format     Abstract available


  45. MANTSO T, Sfakianos AP, Atkinson A, Anestopoulos I, et al
    Development of a Novel Experimental In Vitro Model of Isothiocyanate-induced Apoptosis in Human Malignant Melanoma Cells.
    Anticancer Res. 2016;36:6303-6309.
    PubMed     Text format     Abstract available


    November 2016
  46. MARTON A, Kusz E, Kolozsi C, Tubak V, et al
    Vanillin Analogues o-Vanillin and 2,4,6-Trihydroxybenzaldehyde Inhibit NFkB Activation and Suppress Growth of A375 Human Melanoma.
    Anticancer Res. 2016;36:5743-5750.
    PubMed     Text format     Abstract available


    October 2016
  47. SHAVERDIAN N, Wang J, Levin-Epstein R, Schaue D, et al
    Pro-inflammatory State Portends Poor Outcomes with Stereotactic Radiosurgery for Brain Metastases.
    Anticancer Res. 2016;36:5333-5337.
    PubMed     Text format     Abstract available


    September 2016
  48. BASNET A, Saad N, Benjamin S
    A Case of Vanishing Brain Metastasis in a Melanoma Patient on Nivolumab.
    Anticancer Res. 2016;36:4795-8.
    PubMed     Text format     Abstract available


  49. DONIZY P, Biecek P, Halon A, Matkowski R, et al
    BILLCD8 - A Multivariable Survival Model as a Simple and Clinically Useful Prognostic Tool to Identify High-risk Cutaneous Melanoma Patients.
    Anticancer Res. 2016;36:4739-47.
    PubMed     Text format     Abstract available


  50. RAICA M, Jitariu AA, Cimpean AM
    Lymphangiogenesis and Anti-lymphangiogenesis in Cutaneous Melanoma.
    Anticancer Res. 2016;36:4427-35.
    PubMed     Text format     Abstract available


    August 2016

  51. Melanoma.
    Anticancer Res. 2016;36:4377.
    PubMed     Text format    



  52. Genetics of Melanoma.
    Anticancer Res. 2016;36:4374.
    PubMed     Text format    


    July 2016
  53. LUO H, Umebayashi M, Doi K, Morisaki T, et al
    Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells.
    Anticancer Res. 2016;36:3585-9.
    PubMed     Text format     Abstract available


  54. CALIK J, Pula B, Piotrowska A, Wojnar A, et al
    Prognostic Significance of NOGO-A/B and NOGO-B Receptor Expression in Malignant Melanoma - A Preliminary Study.
    Anticancer Res. 2016;36:3401-7.
    PubMed     Text format     Abstract available


  55. TANG T, Eldabaje R, Yang L
    Current Status of Biological Therapies for the Treatment of Metastatic Melanoma.
    Anticancer Res. 2016;36:3229-41.
    PubMed     Text format     Abstract available


  56. SAMARA P, Skopeliti M, Tsiatas ML, Georgaki S, et al
    A Cytokine Cocktail Augments the Efficacy of Adoptive NK-92 Cell Therapy Against Mouse Xenografts of Human Cancer.
    Anticancer Res. 2016;36:3373-82.
    PubMed     Text format     Abstract available


  57. YAMASHITA K, Hasegawa H, Fujita M, Nishi M, et al
    Host CD40 Is Essential for DCG Treatment Against Metastatic Lung Cancer.
    Anticancer Res. 2016;36:3659-65.
    PubMed     Text format     Abstract available


    June 2016
  58. GORKA E, Fabo D, Gezsi A, Czirbesz K, et al
    Distance from Primary Tumor Is the Strongest Predictor for Early Onset of Brain Metastases in Melanoma.
    Anticancer Res. 2016;36:3065-9.
    PubMed     Text format     Abstract available


  59. YAN S, Coffing BN, Li Z, Xie H, et al
    Diagnostic and Prognostic Value of ProEx C and GLUT1 in Melanocytic Lesions.
    Anticancer Res. 2016;36:2871-80.
    PubMed     Text format     Abstract available


    May 2016
  60. ORNAT M, Kobierzycki C, Grzegrzolka J, Pula B, et al
    SOX18 Expression in Non-melanoma Skin Cancer.
    Anticancer Res. 2016;36:2379-83.
    PubMed     Text format     Abstract available


  61. ESPELI V, Ruegg E, Hottinger AF, Modarressi A, et al
    Weekly Multi-agent Chemotherapy (CMF-b) for Advanced Non-melanoma Skin Cancer.
    Anticancer Res. 2016;36:2359-64.
    PubMed     Text format     Abstract available


  62. KIM JK, Kang KA, Ryu YS, Piao MJ, et al
    Induction of Endoplasmic Reticulum Stress via Reactive Oxygen Species Mediated by Luteolin in Melanoma Cells.
    Anticancer Res. 2016;36:2281-9.
    PubMed     Text format     Abstract available


    April 2016
  63. WOJCIECHOWSKA-ZDROJOWY M, Szepietowski JC, Matusiak L, Dziegiel P, et al
    Expression of Podoplanin in Non-melanoma Skin Cancers and Actinic Keratosis.
    Anticancer Res. 2016;36:1591-7.
    PubMed     Text format     Abstract available


  64. HINTSALA HR, Jokinen E, Haapasaari KM, Moza M, et al
    Nrf2/Keap1 Pathway and Expression of Oxidative Stress Lesions 8-hydroxy-2'-deoxyguanosine and Nitrotyrosine in Melanoma.
    Anticancer Res. 2016;36:1497-506.
    PubMed     Text format     Abstract available


    January 2016
  65. ADAMS S, Lin J, Brown D, Shriver CD, et al
    Ultraviolet Radiation Exposure and the Incidence of Oral, Pharyngeal and Cervical Cancer and Melanoma: An Analysis of the SEER Data.
    Anticancer Res. 2016;36:233-7.
    PubMed     Text format     Abstract available


    December 2015
  66. DECOSTER L, Vande Broek I, Neyns B, Majois F, et al
    Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma.
    Anticancer Res. 2015;35:6893-9.
    PubMed     Text format     Abstract available


  67. BARAK V, Leibovici V, Peretz T, Kalichman I, et al
    Assessing Response to New Treatments and Prognosis in Melanoma Patients, by the Biomarker S-100beta.
    Anticancer Res. 2015;35:6755-60.
    PubMed     Text format     Abstract available


    November 2015
  68. KRAJSOVA I, Arenberger P, Lakomy R, Kubala E, et al
    Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma.
    Anticancer Res. 2015;35:6303-10.
    PubMed     Text format     Abstract available


  69. HU WP, Hsu CC, Wang YC, Senadi GC, et al
    Bis(phenylidenebenzeneamine)-1-disulfide Derivatives Induce Autophagy in Melanoma Cells Through a Mitochondria-mediated Pathway.
    Anticancer Res. 2015;35:6075-80.
    PubMed     Text format     Abstract available


    October 2015
  70. PAP M, Bator J, Szeberenyi J
    Sensitivity of Human Malignant Melanoma Cell Lines to Newcastle Disease Virus.
    Anticancer Res. 2015;35:5401-6.
    PubMed     Text format     Abstract available


  71. PROVINCIALI M, Pierpaoli E, Bartozzi B, Bernardini G, et al
    Zinc Induces Apoptosis of Human Melanoma Cells, Increasing Reactive Oxygen Species, p53 and FAS Ligand.
    Anticancer Res. 2015;35:5309-16.
    PubMed     Text format     Abstract available


  72. VETVICKA V, Vetvickova J
    Glucan Supplementation Has Strong Anti-melanoma Effects: Role of NK Cells.
    Anticancer Res. 2015;35:5287-92.
    PubMed     Text format     Abstract available


    September 2015
  73. HAN SM, Park CW, Ahn JO, Park SC, et al
    Pro-apoptotic and Growth-inhibitory Effect of IFN-beta-Overexpressing Canine Adipose Tissue-derived Mesenchymal Stem Cells Against Melanoma Cells.
    Anticancer Res. 2015;35:4749-56.
    PubMed     Text format     Abstract available


    August 2015
  74. OTSUBO D, Yamashita K, Fujita M, Nishi M, et al
    Early-phase Treatment by Low-dose 5-Fluorouracil or Primary Tumor Resection Inhibits MDSC-mediated Lung Metastasis Formation.
    Anticancer Res. 2015;35:4425-31.
    PubMed     Text format     Abstract available


    July 2015
  75. ZHANG L, Agarwal S, Shohet JM, Zage PE, et al
    CD114 Expression Mediates Melanoma Tumor Cell Growth and Treatment Resistance.
    Anticancer Res. 2015;35:3787-92.
    PubMed     Text format     Abstract available


  76. ADINOLFI B, Carpi S, Romanini A, DA Pozzo E, et al
    Analysis of the Antitumor Activity of Clotrimazole on A375 Human Melanoma Cells.
    Anticancer Res. 2015;35:3781-6.
    PubMed     Text format     Abstract available


    June 2015
  77. KUCERA R, Topolcan O, Treskova I, Kinkorova J, et al
    Evaluation of IL-2, IL-6, IL-8 and IL-10 in Malignant Melanoma Diagnostics.
    Anticancer Res. 2015;35:3537-41.
    PubMed     Text format     Abstract available


  78. ZHANG L, Xie Q, Shan SJ, Tabor MK, et al
    Reduced Expression of RECK Protein May Help Differentiate Cutaneous Malignant Melanoma from Melanocytic Nevus.
    Anticancer Res. 2015;35:3185-91.
    PubMed     Text format     Abstract available


    May 2015

  79. BRAF Targets in Melanoma. Biological Mechanisms, Resistance, and Drug Delivery.
    Anticancer Res. 2015;35:3113.
    PubMed     Text format    


  80. WOZNIAK M, Sztiller-Sikorska M, Czyz M
    Expression of miRNAs as Important Element of Melanoma Cell Plasticity in Response to Microenvironmental Stimuli.
    Anticancer Res. 2015;35:2747-58.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: